Digital health app plus semaglutide 2.4 mg achieves real-world weight loss maintenance over long-term follow-up | Research

The takeaway

Real-world study of semaglutide 2.4 mg users enrolled in the WeGoTogether digital self-support app evaluates long-term weight loss effectiveness with technology-enhanced self-management.

Digital + drug combination
Real-world semaglutide 2.4 mg outcomes with digital self-support app engagement—testing whether technology can close the gap between trial and real-world weight loss

What the researchers found

Semaglutide 2.4 mg + digital self-support app (WeGoTogether). Real-world weight loss effectiveness. Long-term follow-up. Digital health engagement assessed.

Why it matters

Digital health tools could solve the adherence and behavioral support gaps that limit real-world GLP-1 drug effectiveness versus clinical trials.

How the study worked

Real-world study of semaglutide 2.4 mg users enrolled in WeGoTogether digital self-support application.

What this study cannot tell us

Real-world observational. Self-selected digital app users. Cannot separate drug from app effects without control group.

How to read the evidence

Real-world observational with digital health component.

When this study was published

Published in 2025.

The bigger picture

Combining GLP-1 drugs with digital health support represents the future of obesity management—scalable behavioral intervention alongside pharmacotherapy.

Questions still open

Does digital engagement predict better weight loss on semaglutide?
Could digital support partially substitute for clinical visits?
Which app features drive the best outcomes?

Common questions

Can an app help with weight loss drug results?

This study tested exactly that—whether using a digital support app alongside semaglutide improved real-world weight loss. The combination addresses a known gap: real-world weight loss is typically less than in clinical trials, partly because patients lack the intensive support trials provide.

What is WeGoTogether?

WeGoTogether is a digital self-support application designed for patients taking semaglutide for weight management. It provides tracking tools, behavioral support, and self-management resources to help patients maintain the lifestyle changes that maximize their medication's effectiveness.

Read the original research

Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application.

Advances in therapy, 42(10), 5010-5022

View on PubMed ↗Publisher’s paper ↗

Citation

Toliver, Joshua C; Divino, Victoria; Ng, Carmen D; Wang, Julia. (2025). Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application.. Advances in therapy, 42(10), 5010-5022. https://doi.org/10.1007/s12325-025-03325-1